Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan
Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. Methods The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 a...
Saved in:
| Published in | BMC endocrine disorders Vol. 19; no. 1; pp. 36 - 9 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
05.04.2019
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1472-6823 1472-6823 |
| DOI | 10.1186/s12902-019-0362-7 |
Cover
| Abstract | Background
This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan.
Methods
The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013.
Results
During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (
P
< 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23–1.75;
P
< 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38–2.06;
P
< 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12–1.71;
P
< 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00–8.18;
P
< 0.001) were independent predictors for the development of TD.
Conclusions
PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. |
|---|---|
| AbstractList | This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan.
The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013.
During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23-1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38-2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12-1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00-8.18; P < 0.001) were independent predictors for the development of TD.
PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. Methods The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013. Results During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23–1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38–2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12–1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00–8.18; P < 0.001) were independent predictors for the development of TD. Conclusions PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan.BACKGROUNDThis study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan.The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013.METHODSThe data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013.During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23-1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38-2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12-1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00-8.18; P < 0.001) were independent predictors for the development of TD.RESULTSDuring the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23-1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38-2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12-1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00-8.18; P < 0.001) were independent predictors for the development of TD.PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter.CONCLUSIONSPEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. Methods The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013. Results During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD ( P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23–1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38–2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12–1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00–8.18; P < 0.001) were independent predictors for the development of TD. Conclusions PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age ([+ or -] 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013. During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23-1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38-2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12-1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00-8.18; P < 0.001) were independent predictors for the development of TD. PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. Methods The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age ([+ or -] 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013. Results During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23-1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38-2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12-1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00-8.18; P < 0.001) were independent predictors for the development of TD. Conclusions PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. Keywords: Hepatitis C infection, Thyroid dysfunction, Epidemiology, Interferon, Ribavirin, Morbidity Abstract Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. Methods The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001 and 2013. CHC patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV) were enrolled as case patients, and nontreated CHC patients were enrolled as controls and were matched at a control:case ratio of 3:1 by index date, age (± 3 years), and sex. We compared the cumulative incidence of TD between the cohorts at follow-up until 2013. Results During the study period, 3810 cases and 9393 controls were included in the study. Among the study subjects, 173 (4.5%) case patients and 244 (2.6%) controls were diagnosed with TD during the follow-up period. The types of TD were hypothyroidism (42.9%), hyperthyroidism (31.2%), and thyroiditis (25.9%). Compared to controls during the 13-year follow-up, patients treated with PEG-IFN/RBV had a higher incidence rate of TD (P < 0.0001), as determined using the Kaplan-Meier method. Cox proportional hazards regression analysis showed that female sex (adjusted hazard ratio (HR): 1.49; 95% confidence interval (CI): 1.23–1.75; P < 0.001), treatment with PEG-IFN/RBV (HR: 1.68; 95% CI: 1.38–2.06; P < 0.001), hyperlipidemia (HR: 1.38; 95% CI: 1.12–1.71; P < 0.001), and past history of goiter (HR: 6.40; 95% CI: 5.00–8.18; P < 0.001) were independent predictors for the development of TD. Conclusions PEG-IFN/RBV treatment may be an independent risk factor for thyroid dysfunction among patients with hepatitis C virus (HCV) infection. Monitoring thyroid function keenly during PEG-IFN/RBV therapy in patients with chronic HCV infection is recommended for clinicians, especially for female patients and for patients with a history of hyperlipidemia and goiter. |
| ArticleNumber | 36 |
| Audience | Academic |
| Author | Chang, Yu-Kang Tseng, Yuan-Tsung Chen, Kow-Tong Chen, Kou-Huang |
| Author_xml | – sequence: 1 givenname: Yu-Kang surname: Chang fullname: Chang, Yu-Kang organization: Department of Radiology, Chi Mei Medical Center – sequence: 2 givenname: Yuan-Tsung surname: Tseng fullname: Tseng, Yuan-Tsung organization: Department of Medical Research, Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation) – sequence: 3 givenname: Kou-Huang surname: Chen fullname: Chen, Kou-Huang organization: School of Mechanical & Electrical Engineering, Sanming University – sequence: 4 givenname: Kow-Tong surname: Chen fullname: Chen, Kow-Tong email: ktchen@mail.ncku.edu.tw organization: Department of Occupational Medicine, Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation), Department of Public Health, College of Medicine, National Cheng Kung University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30953492$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstu1TAQhiNURC_wAGyQJTZsUjy2EycbpKriUqkSm7K2fHw5xyWxD7bT6jxRXxOHlN4ECGURa_zN75n557Da88GbqnoN-Biga98nID0mNYa-xrQlNX9WHQDjpG47QvcenPerw5QuMQbeEfyi2qe4byjryUF1cx78us4mjihMWYXRJCS9RtGl78hKlUNMKFiUN7sYnEZ6l-zkVXbBIz1F59doa9a7QWajkfNFyJpY7haNlbxyhUE5GplH43NB0FZmV44JXbu8QWpTcKfQxszx7BI6LZA1yxMFv5DuWvqX1XMrh2Re3f6Pqm-fPl6cfqnPv34-Oz05r1WLaa7tyuLOcqZ1Q43ueMelWTW97myjFMG8N4RhLRlwRTUBzRhYUEA7KAOU1NCj6mzR1UFeim10o4w7EaQTvwIhroWM2anBCMk6IEAxMVwyw0EyLLVqATBQZZktWmTRmvxW7q7lMNwJAhazg2JxUBQHxeyg4CXpw5K0nVaj0apMKsrhUSWPb7zbiHW4Ei1rgJR6jqp3twIx_JhMymJ0SZlhkN6EKQlCMGs7TqAt6Nsn6GWYoi_zLRSU7el5C_fUWpauizehvKtmUXHSdBR62vSz1vEfqPJpMzpV9ta6En-U8OZho3cd_t7NAsACqBhSisb-1_T4kxzlspxXqVTjhn9m3pqVtvNWm3g_i78n_QR31hnC |
| CitedBy_id | crossref_primary_10_1186_s43094_020_00085_3 crossref_primary_10_1186_s12884_020_02903_1 crossref_primary_10_4103_trp_trp_35_20 crossref_primary_10_3390_biomedicines12081788 crossref_primary_10_3389_fendo_2022_949003 crossref_primary_10_1002_hsr2_2055 crossref_primary_10_14341_probl12747 crossref_primary_10_3389_fimmu_2022_992819 crossref_primary_10_1002_jmv_25931 crossref_primary_10_3390_biology12010023 crossref_primary_10_1016_j_mce_2020_111097 |
| Cites_doi | 10.5582/bst.2015.01033 10.1046/j.1365-2265.1999.00686.x 10.1046/j.1365-2893.1999.6120139.x 10.1530/eje.0.1460743 10.1080/14787210.2017.1354697 10.1016/S0168-8278(96)80184-X 10.1186/s12872-016-0300-9 10.3904/kjim.2015.30.6.792 10.1016/j.amjmed.2004.01.023 10.1038/ncpendmet1027 10.18632/oncotarget.25092 10.1016/S2468-1253(16)30080-2 10.15403/jgld.2014.1121.252.chc 10.1155/2015/952729 10.1111/j.1469-0691.2009.02937.x 10.1111/j.2517-6161.1972.tb00899.x 10.1046/j.1365-2265.1996.751768.x 10.1099/0022-1317-79-10-2381 10.4049/jimmunol.168.5.2470 10.1053/hupa.2001.28228 10.1016/S0016-5085(03)00394-9 10.1097/MD.0000000000006984 10.1111/j.1365-2893.2005.00655.x 10.1016/S0168-8278(99)80367-5 10.1016/j.jfma.2015.06.012 10.1016/S0168-8278(99)80239-6 10.1016/j.ecl.2007.07.001 10.1089/jir.2011.0101 10.1016/j.ejim.2016.12.015 10.1007/s12020-017-1373-7 10.7326/0003-4819-68-2-338 10.2174/1381612024607018 10.1155/2012/980942 10.1111/j.1440-1746.2009.05874.x 10.1210/jc.2004-0627 10.1136/gut.2005.076646 10.1086/592579 10.1002/hep.1840180205 10.1016/S0002-9343(96)00259-8 10.1111/jgh.12313 10.14310/horm.2002.1707 10.1007/s12072-015-9629-x 10.3350/cmh.2016.22.1.76 10.1371/journal.pone.0055364 10.1016/j.mcna.2012.01.012 10.1111/j.1440-1746.2008.05690.x 10.1136/gut.52.3.425 10.1089/105072503322238809 10.1111/j.1440-1746.2006.04771.x 10.1089/thy.2006.16.563 10.7326/0003-4819-140-5-200403020-00010 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1186/s12902-019-0362-7 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals (ODIN) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1472-6823 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_a48121302e7a4e71a40adc611013cf4f 10.1186/s12902-019-0362-7 PMC6451221 A583193596 30953492 10_1186_s12902_019_0362_7 |
| Genre | Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GrantInformation_xml | – fundername: Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation), Tainan, Taiwan grantid: 106-2 – fundername: ; grantid: 106-2 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM PMFND 3V. 7QP 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI 7X8 5PM 2VQ 4.4 ADTOC AHSBF C1A H13 IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c603t-fbf08f74dd53ed8787aeb59d8f5cc2079e240da417c3d21d441f1c1381036a3e3 |
| IEDL.DBID | M48 |
| ISSN | 1472-6823 |
| IngestDate | Wed Aug 27 01:32:48 EDT 2025 Wed Aug 20 00:01:44 EDT 2025 Tue Sep 30 16:56:54 EDT 2025 Fri Sep 05 05:04:17 EDT 2025 Sat Jul 26 01:20:33 EDT 2025 Tue Jun 17 21:37:36 EDT 2025 Tue Jun 10 20:47:28 EDT 2025 Thu Apr 03 06:53:47 EDT 2025 Wed Oct 01 02:21:05 EDT 2025 Thu Apr 24 23:00:11 EDT 2025 Sat Sep 06 07:29:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Thyroid dysfunction Hepatitis C infection Interferon Epidemiology Ribavirin Morbidity |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-fbf08f74dd53ed8787aeb59d8f5cc2079e240da417c3d21d441f1c1381036a3e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://bmcendocrdisord.biomedcentral.com/track/pdf/10.1186/s12902-019-0362-7 |
| PMID | 30953492 |
| PQID | 2211479761 |
| PQPubID | 44656 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a48121302e7a4e71a40adc611013cf4f unpaywall_primary_10_1186_s12902_019_0362_7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6451221 proquest_miscellaneous_2204687216 proquest_journals_2211479761 gale_infotracmisc_A583193596 gale_infotracacademiconefile_A583193596 pubmed_primary_30953492 crossref_primary_10_1186_s12902_019_0362_7 crossref_citationtrail_10_1186_s12902_019_0362_7 springer_journals_10_1186_s12902_019_0362_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-05 |
| PublicationDateYYYYMMDD | 2019-04-05 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC endocrine disorders |
| PublicationTitleAbbrev | BMC Endocr Disord |
| PublicationTitleAlternate | BMC Endocr Disord |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | World Health Organization (362_CR1) 1999; 6 HA Trans (362_CR13) 2009; 24 KM Jamil (362_CR32) 2009; 24 Y Tomer (362_CR9) 2007; 36 G Fattovich (362_CR15) 1996; 24 C Nair Kesavachandran (362_CR43) 2013; 8 Y Hwang (362_CR28) 2015; 30 DO Yetkin (362_CR50) 2015; 2015 362_CR26 362_CR25 HS Huang (362_CR57) 2017; 57 PC Tsai (362_CR22) 2007; 96 CY Dai (362_CR52) 2015; 30 EASL (European Association on the studies on the Liver) (362_CR3) 1999; 31 M Zhou (362_CR4) 2015; 9 M Cybulsky (362_CR30) 2016; 16 C Hultgren (362_CR11) 1998; 79 A Antonelli (362_CR47) 2004; 117 Korean Association for the Study of the Liver (362_CR5) 2016; 22 E Roti (362_CR19) 1996; 101 H Fontaine (362_CR16) 2001; 32 SH Wang (362_CR18) 2002; 168 LH Duntas (362_CR55) 2012; 96 HA Tran (362_CR27) 2007; 22 A Antonelli (362_CR39) 2006; 16 Z Yan (362_CR45) 2012; 12 SG Lim (362_CR23) 2017; 2 ML Polo (362_CR6) 2017; 15 LH Duntas (362_CR51) 2016; 15 A Antonelli (362_CR46) 2009; 5 Y Shen (362_CR7) 2016; 25 C Carella (362_CR12) 2004; 89 M Marazuela (362_CR35) 1996; 44 D Choubey (362_CR37) 2011; 31 A Tran (362_CR38) 1993; 18 D Siagris (362_CR53) 2006; 3 MP Manns (362_CR17) 2006; 55 AP Delitala (362_CR49) 2017; 38 JH Kao (362_CR33) 2016; 115 B Batsaikhan (362_CR54) 2018; 9 H Muñoz (362_CR40) 2004; 23 A Ascione (362_CR10) 2002; 8 MF Prummel (362_CR48) 2003; 13 HH Lin (362_CR24) 2010; 16 Y Hwang (362_CR44) 2015; 30 H Bennett (362_CR20) 2015; 9 MJ Huang (362_CR8) 1999; 50 AL Zignego (362_CR2) 1999; 31 C Carella (362_CR34) 2002; 146 CH Liu (362_CR21) 2008; 47 AD Steinberg (362_CR56) 1968; 68 DR Cox (362_CR31) 1972; 34 U Siebert (362_CR42) 2003; 52 AL Zignego (362_CR36) 2012; 2012 MW Russo (362_CR14) 2003; 124 SJ Hadziyannis (362_CR41) 2004; 140 D Kozielewicz (362_CR29) 2017; 71 |
| References_xml | – volume: 9 start-page: 97 year: 2015 ident: 362_CR4 publication-title: Biosci Trends doi: 10.5582/bst.2015.01033 – volume: 50 start-page: 503 year: 1999 ident: 362_CR8 publication-title: Clin Endocrinol doi: 10.1046/j.1365-2265.1999.00686.x – volume: 6 start-page: 35 year: 1999 ident: 362_CR1 publication-title: J Viral Hepat doi: 10.1046/j.1365-2893.1999.6120139.x – volume: 146 start-page: 743 year: 2002 ident: 362_CR34 publication-title: Eur J Endocrinol doi: 10.1530/eje.0.1460743 – ident: 362_CR26 – volume: 15 start-page: 737 year: 2017 ident: 362_CR6 publication-title: Expert Rev Anti-Infect Ther doi: 10.1080/14787210.2017.1354697 – volume: 24 start-page: 38 year: 1996 ident: 362_CR15 publication-title: J Hepatol doi: 10.1016/S0168-8278(96)80184-X – volume: 16 start-page: 122 year: 2016 ident: 362_CR30 publication-title: BMC Cardiovasc Disord doi: 10.1186/s12872-016-0300-9 – volume: 30 start-page: 792 year: 2015 ident: 362_CR28 publication-title: Korean J Intern Med. doi: 10.3904/kjim.2015.30.6.792 – volume: 117 start-page: 10 year: 2004 ident: 362_CR47 publication-title: Am J Med doi: 10.1016/j.amjmed.2004.01.023 – volume: 5 start-page: 26 year: 2009 ident: 362_CR46 publication-title: Nat Clin Pract Endocrinol Metab doi: 10.1038/ncpendmet1027 – volume: 9 start-page: 21313 year: 2018 ident: 362_CR54 publication-title: Oncotarget. doi: 10.18632/oncotarget.25092 – volume: 2 start-page: 52 year: 2017 ident: 362_CR23 publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(16)30080-2 – volume: 25 start-page: 227 year: 2016 ident: 362_CR7 publication-title: J Gastrointestin Liver Dis doi: 10.15403/jgld.2014.1121.252.chc – volume: 2015 year: 2015 ident: 362_CR50 publication-title: Int J Endocrinol doi: 10.1155/2015/952729 – volume: 12 year: 2012 ident: 362_CR45 publication-title: Hepat Mon – volume: 16 start-page: 663 year: 2010 ident: 362_CR24 publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2009.02937.x – ident: 362_CR25 – volume: 34 start-page: 187 year: 1972 ident: 362_CR31 publication-title: J R Stat Soc Series B Stat Methodol doi: 10.1111/j.2517-6161.1972.tb00899.x – volume: 44 start-page: 635 year: 1996 ident: 362_CR35 publication-title: Clin Endocrinol doi: 10.1046/j.1365-2265.1996.751768.x – volume: 79 start-page: 2381 year: 1998 ident: 362_CR11 publication-title: J Gen Virol doi: 10.1099/0022-1317-79-10-2381 – volume: 168 start-page: 2470 year: 2002 ident: 362_CR18 publication-title: J Immunol doi: 10.4049/jimmunol.168.5.2470 – volume: 32 start-page: 904 year: 2001 ident: 362_CR16 publication-title: Hum Pathol doi: 10.1053/hupa.2001.28228 – volume: 124 start-page: 1711 year: 2003 ident: 362_CR14 publication-title: Gastroenterology doi: 10.1016/S0016-5085(03)00394-9 – volume: 96 start-page: e6984 year: 2007 ident: 362_CR22 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000006984 – volume: 3 start-page: 56 year: 2006 ident: 362_CR53 publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00655.x – volume: 31 start-page: 3 year: 1999 ident: 362_CR3 publication-title: J Hepatol doi: 10.1016/S0168-8278(99)80367-5 – volume: 115 start-page: 65 year: 2016 ident: 362_CR33 publication-title: J Formos Med Assoc doi: 10.1016/j.jfma.2015.06.012 – volume: 31 start-page: 369 year: 1999 ident: 362_CR2 publication-title: J Hepatol doi: 10.1016/S0168-8278(99)80239-6 – volume: 36 start-page: 1051 year: 2007 ident: 362_CR9 publication-title: Endocrinol Metabol Clin North Am doi: 10.1016/j.ecl.2007.07.001 – volume: 31 start-page: 857 year: 2011 ident: 362_CR37 publication-title: J Interf Cytokine Res doi: 10.1089/jir.2011.0101 – volume: 38 start-page: 17 year: 2017 ident: 362_CR49 publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2016.12.015 – volume: 57 start-page: 436 year: 2017 ident: 362_CR57 publication-title: Endocrine. doi: 10.1007/s12020-017-1373-7 – volume: 68 start-page: 338 year: 1968 ident: 362_CR56 publication-title: Ann Intern Med doi: 10.7326/0003-4819-68-2-338 – volume: 8 start-page: 977 year: 2002 ident: 362_CR10 publication-title: Curr Pharm Des doi: 10.2174/1381612024607018 – volume: 2012 start-page: 980942 year: 2012 ident: 362_CR36 publication-title: Clin Dev Immunol doi: 10.1155/2012/980942 – volume: 24 start-page: 1163 year: 2009 ident: 362_CR13 publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2009.05874.x – volume: 89 start-page: 3656 year: 2004 ident: 362_CR12 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2004-0627 – volume: 55 start-page: 1350 year: 2006 ident: 362_CR17 publication-title: Gut doi: 10.1136/gut.2005.076646 – volume: 47 start-page: 1260 year: 2008 ident: 362_CR21 publication-title: Clin Infect Dis doi: 10.1086/592579 – volume: 18 start-page: 253 year: 1993 ident: 362_CR38 publication-title: Hepatology doi: 10.1002/hep.1840180205 – volume: 101 start-page: 482 year: 1996 ident: 362_CR19 publication-title: Am J Med doi: 10.1016/S0002-9343(96)00259-8 – volume: 30 start-page: 879 year: 2015 ident: 362_CR52 publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12313 – volume: 15 start-page: 500 year: 2016 ident: 362_CR51 publication-title: Hormones (Athens) doi: 10.14310/horm.2002.1707 – volume: 9 start-page: 378 year: 2015 ident: 362_CR20 publication-title: Hepatol Int doi: 10.1007/s12072-015-9629-x – volume: 71 start-page: 555 year: 2017 ident: 362_CR29 publication-title: Przegl Epidemiol – volume: 22 start-page: 76 year: 2016 ident: 362_CR5 publication-title: Clin Mol Hepatol doi: 10.3350/cmh.2016.22.1.76 – volume: 8 start-page: e55364 year: 2013 ident: 362_CR43 publication-title: PLoS One doi: 10.1371/journal.pone.0055364 – volume: 30 start-page: 792 year: 2015 ident: 362_CR44 publication-title: Korean J Intern Med doi: 10.3904/kjim.2015.30.6.792 – volume: 96 start-page: 269 year: 2012 ident: 362_CR55 publication-title: Med Clin North Am doi: 10.1016/j.mcna.2012.01.012 – volume: 24 start-page: 1017 year: 2009 ident: 362_CR32 publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2008.05690.x – volume: 52 start-page: 425 year: 2003 ident: 362_CR42 publication-title: Gut. doi: 10.1136/gut.52.3.425 – volume: 13 start-page: 547 year: 2003 ident: 362_CR48 publication-title: Thyroid. doi: 10.1089/105072503322238809 – volume: 22 start-page: 472 year: 2007 ident: 362_CR27 publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2006.04771.x – volume: 23 start-page: 61 year: 2004 ident: 362_CR40 publication-title: Health Sci J – volume: 16 start-page: 563 year: 2006 ident: 362_CR39 publication-title: Thyroid. doi: 10.1089/thy.2006.16.563 – volume: 140 start-page: 346 year: 2004 ident: 362_CR41 publication-title: Ann Intern Med doi: 10.7326/0003-4819-140-5-200403020-00010 |
| SSID | ssj0017820 |
| Score | 2.2130375 |
| Snippet | Background
This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in... This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. The... Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in... This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. The... This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in... Abstract Background This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC)... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 36 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Ambulatory care Antiviral Agents - adverse effects Antiviral drugs Biological response modifiers Cardiovascular disease Case-Control Studies Cholesterol Chronic infection Codes Diabetes Drug Therapy, Combination Endocrinology Epidemiology Epidemiology of Endocrine Disorders Female Follow-Up Studies Goiter Health Health insurance Health risk assessment Hepacivirus - drug effects Hepatitis Hepatitis C Hepatitis C infection Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Hormones Humans Hyperlipidemia Hyperthyroidism Hypothyroidism Immunology Incidence Infection Infections Insurance Interferon Interferon-alpha - adverse effects Lipids Male Medical research Medicine Medicine & Public Health Metabolic Diseases Metabolism Middle Aged Morbidity National health insurance Patient outcomes Patients Polyethylene Glycols - adverse effects Prognosis Recombinant Proteins - adverse effects Regression analysis Research Article Ribavirin Ribavirin - adverse effects Risk Factors rology Sex ratio Taiwan Thyroid Thyroid diseases Thyroid Diseases - chemically induced Thyroid Diseases - epidemiology Thyroid Diseases - pathology Thyroid dysfunction Thyroid gland Thyroid hormones Thyroiditis Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (ODIN) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhz4Ope-6TYsKhUKDiWWNJfuYhoZQmp4SyE3IkpwsLPay3m3YX9S_2Rnb665bSC69SmNb8nyaGUmjT4x99JmVUAoVZ8K7GLIixCVayFgpILYbAEjoNPLZD3V6Ad8us8udq74oJ6ynB-5_3KGFnFjHkjRoC0ELC4n1TqHXEtJVUJH1RTe2nUwN-wfEAjfsYYpcHba02kIpCEXcHRPSEy_UkfX_a5J3fNLf-ZLjpukj9mBdL-zmxs7nO37p5Al7PASU_KjvyFN2L9TP2P2zYcv8Ofv1vamvYjLAvFmvEF-h5bb2nHLK-XDbDm8qjgpbNjPP_aYlX0f64v0ZRr4IV5s5xqSeE7nEsgpLrOvfUdqfM5ThY746ivCBq7XltMjLXU-_y68Dla9mLT_m2xSwmsTP7ezG1i_YxcnX8-PTeLidIXYqkau4KqskrzR4n8ngcxz4NpRZ4fMqcy5NdBEwWPAWhHbSp8Jj3FUJJ4hRTCorg3zJ9uqmDq8Z14kF7yB3UJQghLdCi9Srokp14WXhI5ZstWXcQF1ON2jMTTeFyZXpFWxQwYYUbHTEPo-PLHrejtuEvxAERkGi3O4KEIhmAKK5C4gR-0QAMmQYsHHODucbsItEsWWOshzNncwKFbH9iSQOaDet3kLQDAalNSlO1EFj7Cgi9mGspicpSa4OzZpkElA5sTFF7FWP2LFLkngFoUgjpidYnvR5WlPPrju6cQUYFKb43YMt6v8065ZfejAOjLsV8OZ_KOAte5h2IxziJNtne6vlOrzDiHFVvu-Mw29VN2aE priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSDwOiFchUJCRkJCoosaxYycnVCqqClFOrbQ3y7Gd7UqrZNnsUu0v4m8yk3jTBqTlGk8ek3naHn9DyAeXGS5KJuOMORuLrPBxCR4yllIg2o0QIsHTyOc_5Nml-DbJJmHBrQ1llVuf2Dlq11hcIz9KYaYiFARP9nnxM8auUbi7Glpo3CX3GKQqqNVqMky4GGLBhZ1MlsujFtdcsBChiLvDQmoUizrI_n8d863I9HfV5LB1-og8WNcLs7k28_mt6HT6hDwOaSU97vXgKbnj62fk_nnYOH9Ofn9v6mmMbpg26xVw7FtqakexspyGnju0qSiIbdnMHHWbFiMeSo32Jxnpwk83c8hMHUWIiWXllzDWP6M0v2ZAQ4eqdSChAbG1pbjUS20PwkuvPF5fzVp6QreFYDWSX5jZtalfkMvTrxcnZ3Ho0RBbmfBVXJVVkldKOJdx73Iwf-PLrHB5lVmbJqrwkDI4I5iy3KXMQfZVMcsQV4xLwz3fJ3t1U_tXhKrECGdFbkVRCsacYYqlThZVqgrHCxeRZCstbQOAOfbRmOtuIpNL3QtYg4A1CliriHwabln06B27iL-gCgyECLzdXWiWUx3sWBuRIwheknplhFfMiMQ4KyGJYtxWoorIR1Qgje4BPs6acMoBWESgLX2c5eD0eFbIiByMKMGs7Xh4q4I6uJVW3xhBRN4Pw3gnlsrVvlkjTSJkjphMEXnZa-zAEkd0QVGkEVEjXR7xPB6pZ1cd6LgUkBqm8N7DrdbffNaOX3o4GMb_BfB6N8tvyMO0s10RJ9kB2Vst1_4tZISr8l1n9n8AkgFejQ priority: 102 providerName: ProQuest – databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gh8P4rfVUyIIgke5pkmT9vFcPA7xfLqDewtpkt4tLO2y7XrsX-S_6UybrVuVE1-TSZt0PjLpzPxCyHuXGS5KJuOMORuLrPBxCRYyllIg2o0QIsFq5NNv8uRcfLnILgJYNNbC7MbvWS4PW_xPgskDRdwX-Kjb5E4Gdhez92ZyNgYMEPYtBC3_Omyy7fTo_H_a4J1N6PcEyTFK-oDcW9dLs7k2i8XORnT8iDwMHiQ9Glj-mNzy9RNy9zTEyJ-SH1-b-jJGi0ubdQcC5VtqakcxiZyG63VoU1Hg0KqZO-o2LW5uyCA6FC3Spb_cLMAJdRTRJFaVX0Hf8IzSfJ8DDR0T1IGEBnDWluJfXWoHvF165bG9m7d0Rrc5XzWSn5n5tamfkfPjz2ezkzhcxxBbmfAursoqySslnMu4dzlouvFlVri8yqxNE1V48A6cEUxZ7lLmwNGqmGUIIcal4Z4_J3t1U_uXhKrECGdFbkVRCsacYYqlThZVqgrHCxeRZMstbQNWOV6ZsdD9mSWXemCwBgZrZLBWEfk4DlkOQB03EX9CERgJEWO7bwDR00FltRE54t0lqVdGeMWMSIyzEvwlxm0lqoh8QAHSaAlgctaEggZYImJq6aMsB_vGs0JGZH9CCRpsp91bEdTBgrQ6hZO5UOAssoi8G7txJGbF1b5ZI00iZI7wSxF5MUjsuCSOQIKiSCOiJrI8WfO0p55f9fjiUoAXmMJ7D7ZS_2taN3zSg1Ex_s2AV__17NfkftqrsoiTbJ_sdau1fwO-YFe-7a3AT41DVv0 priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbKVuJx4P0IFGQkJCSqbOPEsZPjUlFViK04dKVyihzb2a66OKskS7X8If4mnrzYFFSExC2Kx0kcz3wziWc-I_RGhSKgKWFuSJR0aRhrN7UI6TJGge2GUupBNfL0hB3P6Mez8GwHTbtamPSr1EblslA1-eR4uwh9WSO3PZAXByuVNQYfsYMS_qVAgkHs1kVA_AbaZbDeNEK7s5PPky91hRG3DxD5Qbuy-cd-A99UU_j_DtRbnupqFmW_lHoH3VqbldhciuVyy1sd3UOmG2eTpHIxXlfpWH6_QgH5317EfXS3jWvxpFHEB2hHm4fo5rRduX-EfnzKzdwFP4DzdWUvrEssjMKQ2o7bTX9wnmGrN0W-UFhtSnC5oDa4KaXEKz3fLG1orDBwXBSZLmxbc41UfFtYGdynzVsR3FLGlhj-NWPZsADjcw3nq0WJD3GXiWZA_FQsLoV5jGZHH04Pj912kwhXMi-o3CzNvCjjVKkw0Cqy-CN0GsYqykIpfY_H2sYsSlDCZaB8omz4lxFJgNgsYCLQwRM0MrnRzxDmnqBK0kjSOKWEKEE48RWLM5_HKoiVg7xOPRLZMqjDRh7LpP6SiljSTEBiJyCBCUi4g971XVYNfch1wu9B53pBYP6uT-TFPGmBJBE0AhY-z9dcUM2JoJ5QktkojgQyo5mD3oLGJoBPoCGiLbOwQwSmr2QSRhZ1gzBmDtobSFpckcPmTueTFtfKxPft9zO3ISxx0Ou-GXpCrp7R-RpkPMoiIIVy0NPGRPohBUBvSGPfQXxgPIMxD1vM4rxmPWfUxqa-ve9-Z2a_HuuaV7rfW-LfJ-D5P0m_QLf92tSo64V7aFQVa_3SRqhV-qrFnZ-MrIu7 priority: 102 providerName: Unpaywall |
| Title | Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan |
| URI | https://link.springer.com/article/10.1186/s12902-019-0362-7 https://www.ncbi.nlm.nih.gov/pubmed/30953492 https://www.proquest.com/docview/2211479761 https://www.proquest.com/docview/2204687216 https://pubmed.ncbi.nlm.nih.gov/PMC6451221 https://bmcendocrdisord.biomedcentral.com/track/pdf/10.1186/s12902-019-0362-7 https://doaj.org/article/a48121302e7a4e71a40adc611013cf4f |
| UnpaywallVersion | publishedVersion |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: KQ8 dateStart: 20011001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate - eBooks customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals - Free Access to All customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1472-6823 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: M48 dateStart: 20011001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen customDbUrl: eissn: 1472-6823 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017820 issn: 1472-6823 databaseCode: C6C dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1ta9swEBZ9ga77MPY-b13QYDBYcWfZsmR_GKMNLWWsoZQGsn0xsiSngWB3cbIuv2h_c3d-a7N13ZdArFMi-Z47naTTI0LemlAFPGXCDZnRLg9j66bgIV0hOLLdcM49PI18MhDHQ_55FI7WSHu9VfMCy1undnif1HA23fv5ffkJDP5jZfCR-FDiWgomGMRudQhIrpNNGJh8BPkJv95UQGq4ZmPz1mrbZCtA-jUe-yujVEXm_7fLvjFm_ZlP2W2q3if3FvmlWl6p6fTGuHX0kDxoAk66XyPkEVmz-WOyddJsqT8hv74U-dhFB02LxRzwZ0uqckMx55w2t_HQIqOg0FkxMdQsSxwLUZ-0PuNIL-14OYWY1VAkn5hldgZl9W-k6scEZGiXzw4itOFyLSkuAlNd0_PSC4vP55OS9mmbIpaj-LmaXKn8KRkeHZ73j93m9gZXCy-Yu1maeVEmuTFhYE0EjkHZNIxNlIVa-56MLQQTRnEmdWB8ZiAuy5hmyDgWCBXY4BnZyIvcviBUeoobzSPN45QzZhSTzDciznwZmyA2DvFabSW6oTbHGzamSTXFiURS6zoBXSeo60Q65H1X5bLm9bhL-AAh0AkiJXf1oJiNk8bCE8UjpMfzfCsVt5Ip7imjBYRXLNAZzxzyDgGUIJShcVo15x-gi0jBleyHEbjDIIyFQ3ZWJMHg9WpxC8GktZfEh4k8lxBbMoe86YqxJibR5bZYoIzHRYRsTQ55XiO261ILfIfIFSyv9Hm1JJ9cVHTkgkPQ6MP_7raov27WHa90tzOM_yvg5T_b-4ps-5UFc9cLd8jGfLawryFMnKc9si5Hskc2Dw4Hp2fwrS_6vWrJpVe5Bfg8O_gG5cPB6f7X3z--aHQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkBg8IL4JDDASCIkpWhw7dvKA0BhMHWv31El78xzb6SpVSWlaqv5FvPE34svXVpDK017jy4dzP9-d7fPvEHpnIkVZSrgfEaN9FiXWT52F9DlnwHbDGAvgNPLglPfO2Pfz6HwL_W7PwkBaZWsTK0NtCg1r5Puhm6kw4Zwn-Tz94UPVKNhdbUto1LA4saulm7KVn46_Ov2-D8Ojb8PDnt9UFfA1D-jcz9IsiDPBjImoNbEDrLJplJg4i7QOA5FY5-SMYkRoakJiXLyQEU2ACYtyRS11z72FbjMaMODqF-fdBI8A91yzc0pivl_CGg8kPiR-dThJrPm-qkTAv47gmif8O0uz26q9h3YW-VStlmoyueYNjx6g-00Yiw9q3D1EWzZ_hO4Mmo36x-hXv8hHPph9XCzm7g_bEqvcYMhkx02NH1xk2MFkVowNNqsSPCygBNcnJ_HUjlYTFwkbDJQWs8zOXFv9jFT9HDsZ3GXJOxHcMMSWGJaWsa5Jf_GlhevzcYkPcZt4loP4UI2XKn-Czm5Ee0_Rdl7k9jnCIlDMaBZrlqSMEKOIIKHhSRaKxNDEeChotSV1Q5gOdTsmspo4xVzWCpZOwRIULIWHPna3TGu2kE3CXwACnSAQfVcXitlINnZDKhYD6V4QWqGYFUSxQBnNXdBGqM5Y5qEPACAJ5sh9nFbNqQrXRSD2kgdR7IwsjRLuod01SWdG9HpzC0HZmLFSXg06D73tmuFOSM3LbbEAmYDxGDigPPSsRmzXJQpshiwJPSTWsLzW5_WWfHxZkZxz5kLR0L13r0X91Wdt-KV73cD4vwJebO7yG7TTGw76sn98evIS3Q2rccz8INpF2_PZwr5y0eg8fV2ZAIwubtrm_AFlNZuD |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA-6wdQH8WtanRpBEBxlTZsm7eN1epnXbQhusLeQJundhUt7aXsd9y_y3zSnTeuqMvE1OWmTno-c9JzzC0JvdSwjmhHmx0Qrn8ap8TNrIX3GKKDdUEoDqEY-OWVH53R2EV-4e07rPtu9D0l2NQ2A0lQ0ByuddyqesIMa_p5ASkHqt2U__DbaTuKU2dPX9mQy-zYbAgkAB-eCmX8dONqOWtT-P23ztc3p98TJIXp6D91ZFyu5uZLL5bUNavoA3XeeJZ50ovAQ3TLFI7Rz4mLnj9GP47KY-2CJcblu7JpNjWWhMSSXY3ftDi5zbDlXlQuN9aaGTQ8Yh7tiRrwy883SOqcaA8pElZvK9nXPyOT3haXBQ-K6JcEOtLXG8LcXqw6HF18aaG8WNT7EfS5YAeRncnEliyfofPrp7PDId9c0-IoFUePnWR4kOadax5HRibUA0mRxqpM8VioMeGqs16AlJVxFOiTaOmA5UQSgxSImIxPtoq2iLMwzhHkgqVY0UTTNKCFaEk5CzdI85KmOUu2hoOeWUA7DHK7SWIr2LJMw0TFYWAYLYLDgHno_DFl1AB43EX8AERgIAXu7bSiruXCqLCRNAAcvCA2X1HAiaSC1YtaPIpHKae6hdyBAAiyEnZySrtDBLhGwtsQkTqzdi6y4emhvRGk1W427exEUzrLUIrQndsqtE0k89GbohpGQLVeYcg00AWUJwDJ56GknscOSIgAYpGnoIT6S5dGaxz3F4rLFHWfUeoehfe9-L_W_pnXDJ90fFOPfDHj-X89-jXa-fpyK48-nX16gu2Gr1dQP4j201VRr89K6i032ypmEnwjZY6g |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbKVuJx4P0IFGQkJCSqbOPEsZPjUlFViK04dKVyihzb2a66OKskS7X8If4mnrzYFFSExC2Kx0kcz3wziWc-I_RGhSKgKWFuSJR0aRhrN7UI6TJGge2GUupBNfL0hB3P6Mez8GwHTbtamPSr1EblslA1-eR4uwh9WSO3PZAXByuVNQYfsYMS_qVAgkHs1kVA_AbaZbDeNEK7s5PPky91hRG3DxD5Qbuy-cd-A99UU_j_DtRbnupqFmW_lHoH3VqbldhciuVyy1sd3UOmG2eTpHIxXlfpWH6_QgH5317EfXS3jWvxpFHEB2hHm4fo5rRduX-EfnzKzdwFP4DzdWUvrEssjMKQ2o7bTX9wnmGrN0W-UFhtSnC5oDa4KaXEKz3fLG1orDBwXBSZLmxbc41UfFtYGdynzVsR3FLGlhj-NWPZsADjcw3nq0WJD3GXiWZA_FQsLoV5jGZHH04Pj912kwhXMi-o3CzNvCjjVKkw0Cqy-CN0GsYqykIpfY_H2sYsSlDCZaB8omz4lxFJgNgsYCLQwRM0MrnRzxDmnqBK0kjSOKWEKEE48RWLM5_HKoiVg7xOPRLZMqjDRh7LpP6SiljSTEBiJyCBCUi4g971XVYNfch1wu9B53pBYP6uT-TFPGmBJBE0AhY-z9dcUM2JoJ5QktkojgQyo5mD3oLGJoBPoCGiLbOwQwSmr2QSRhZ1gzBmDtobSFpckcPmTueTFtfKxPft9zO3ISxx0Ou-GXpCrp7R-RpkPMoiIIVy0NPGRPohBUBvSGPfQXxgPIMxD1vM4rxmPWfUxqa-ve9-Z2a_HuuaV7rfW-LfJ-D5P0m_QLf92tSo64V7aFQVa_3SRqhV-qrFnZ-MrIu7 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+outcomes+and+risk+factors+of+thyroid+dysfunction+during+pegylated+interferon+and+ribavirin+treatment+in+patients+with+chronic+hepatitis+C+infection+in+Taiwan&rft.jtitle=BMC+endocrine+disorders&rft.au=Chang%2C+Yu-Kang&rft.au=Tseng%2C+Yuan-Tsung&rft.au=Chen%2C+Kou-Huang&rft.au=Chen%2C+Kow-Tong&rft.date=2019-04-05&rft.eissn=1472-6823&rft.volume=19&rft.issue=1&rft.spage=36&rft_id=info:doi/10.1186%2Fs12902-019-0362-7&rft_id=info%3Apmid%2F30953492&rft.externalDocID=30953492 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6823&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6823&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6823&client=summon |